Europe Autologous Cell Therapy Market Size & Outlook
Europe autologous cell therapy market highlights
- The Europe autologous cell therapy market generated a revenue of USD 1,663.7 million in 2024.
- The market is expected to grow at a CAGR of 21% from 2025 to 2030.
- In terms of segment, cancer was the largest revenue generating application in 2024.
- Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Europe data book summary
| Market revenue in 2024 | USD 1,663.7 million |
| Market revenue in 2030 | USD 5,346.8 million |
| Growth rate | 21% (CAGR from 2025 to 2030) |
| Largest segment | Cancer |
| Fastest growing segment | Cancer |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cancer |
Other key industry trends
- In terms of revenue, Europe region accounted for 30.8% of the global autologous cell therapy market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,474.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Autologous Cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Tego Science | View profile | 11-50 | Gangneung, Kangwon-do, South Korea, Asia | http://www.tegoscience.com |
| Caladrius Biosciences | View profile | - | - | |
| Opexa Therapeutics | View profile | 11-50 | Houston, Texas, United States, North America | http://www.opexatherapeutics.com |
| Catalent, Inc | View profile | - | - | - |
| Novartis AG | View profile | - | - | - |
| Bristol Myers Squibb | View profile | - | - | - |
| Corning Incorporated | View profile | - | Corning, New York, United States, North America | https://www.corning.com/ |
| Brainstorm Cell Therapeutics Inc | View profile | 29 | 1325 Avenue of Americas, 28th Floor, New York, NY, United States, 10019 | https://www.brainstorm-cell.com |
| Holostem Terapie Avanzate | View profile | 11-50 | Modena, Emilia-Romagna, Italy, Europe | https://www.holostem.com/ |
| Pharmicell | View profile | 51-100 | Yeoksamdong, Seoul-t'ukpyolsi, South Korea, Asia | http://www.pharmicell.com/ |
| Bio Elpida | View profile | 11-50 | Lyon, Rhone-Alpes, France, Europe | http://www.bio-elpida.com |
| Vericel Corp | View profile | 314 | 64 Sidney Street, Cambridge, MA, United States, 02139 | https://www.vcel.com |
| Sartorius AG | View profile | 14338 | Otto-Brenner-Strasse 20, Gottingen, NI, Germany, 37079 | https://www.sartorius.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Europe autologous cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to autologous cell therapy market will help companies and investors design strategic landscapes.
Cancer was the largest segment with a revenue share of 124.08% in 2024. Horizon Databook has segmented the Europe autologous cell therapy market based on cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Europe autologous cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe autologous cell therapy market databook
-
Our clientele includes a mix of autologous cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe autologous cell therapy market , including forecasts for subscribers. This continent databook contains high-level insights into Europe autologous cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
